Miratas-25 Tablet 10's
₹172.8*
MRP ₹192
10% off
₹163*
MRP ₹192
15% CB
₹29 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Miratas-25 Tablet belongs to the group of medications called ‘urinary antagonists' or 'antispasmodics' primarily used to treat overactive bladder (OAB) symptoms. Overactive bladder is a condition in which the urinary bladder muscles constrict uncontrollably, thereby causing an urgent need to urinate, frequent urination, and an inability to control urination.
Miratas-25 Tablet contains ‘mirabegron’ that relaxes the urinary bladder muscles, which in turn decreases the activity of the overactive bladder. In an overactive bladder, muscle contractions occur before the full expansion of the bladder, causing the patient to have frequent urges to urinate. Miratas-25 Tablet stops these sudden contractions of urinary bladder muscles, thereby enabling control over urination. Thus, it increases the amount and volume of urine that can be held by the bladder.
In some cases, Miratas-25 Tablet may cause common side effects of Miratas-25 Tablet , which are nausea, constipation, diarrhoea, headache, dizziness, and increased heart rate. Most of these side effects do not require medical attention and resolve gradually over time. However, if the side effects persist or worsen, consult a doctor.
Do not take Miratas-25 Tablet if you are allergic to any of its ingredients. Before taking Miratas-25 Tablet , inform your doctor if you have kidney disease, liver disease, hypertension, urinary retention, angioedema, or a history of heart rhythm problems (including QT prolongation). Consult your doctor if you are pregnant or breastfeeding. Avoid driving or operating heavy machinery, as this medicine may cause dizziness.
Miratas-25 Tablet contains 'mirabegron', which belongs to the class of medications called 'anticholinergics'. It can decrease the activity of the overactive bladder. In an overactive bladder, muscle contractions occur before the full expansion of the bladder, causing the patient to have frequent urges to urinate. Miratas-25 Tablet can stop these sudden contractions of bladder muscles. It enables control over urination and increases the amount of urine held by your bladder.
Do not take Miratas-25 Tablet if you are allergic to any ingredients present in it. Before taking Miratas-25 Tablet , inform your doctor if you have kidney disease, liver disease, hypertension, urinary retention, angioedema, or a history of heart rhythm problems (including QT prolongation). Consult your doctor if you are pregnant or breastfeeding. Avoid driving or operating heavy machinery, as this medicine may cause dizziness.
Drug-Drug Interactions: Miratas-25 Tablet may interact with other antifungal drugs (ketoconazole and itraconazole), antihypertensives (carvedilol, metoprolol), antacid (brexpiprazole), anti-psychotic (pimozide, thioridazine), anti-allergic (chlorpheniramine), anti-tussive (dextromethorphan), blood thinners (warfarin, coumadin), anti-depressants (desipramine), anti-arrhythmic (digoxin, flecainide, propafenone), drugs used to treat overactive bladder (darifenacin, fesoterodine, oxybutynin, tolterodine, trospium).
Drug-Food Interactions: Do not take grapefruit or grapefruit juice while using Miratas-25 Tablet .
Drug-Disease Interactions: Miratas-25 Tablet should be used with caution in patients with urinary retention (inability to urinate), heart rhythm problems (including QT prolongation), hypertension, kidney dialysis, severe liver disease, or severe kidney disease.
Overactive bladder (OAB): In normal conditions, when the urinary bladder is filled with urine, it sends a message to the brain that an individual is ready to urinate. During the urination process, bladder muscles contract, which ultimately leads to a uniform flow of urine. Contrary to this, in an overactive bladder (OAB), the urinary bladder muscles start contracting before the urine is filled in the urinary bladder, thereby causing frequent urges to urinate.
Alcohol
Caution
Avoid taking alcohol as it increases the risk of side effects.
Pregnancy
Caution
Miratas-25 Tablet is not recommended for use in pregnant women unless absolutely necessary. Before taking this medicine, the risks and benefits should be discussed with the doctor.
Breast Feeding
Caution
Miratas-25 Tablet is not recommended for use in breastfeeding women unless absolutely necessary. Before taking this medicine, the risks and benefits should be discussed with the doctor. If this medicine is used, close monitoring of the infant for undesired side effects is recommended.
Driving
Caution
The use of this medicine may cause blurred vision or dizziness in some patients. You are advised not to perform any activities, such as driving a vehicle or operating machinery, if you experience any of these symptoms during treatment with this medicine.
Liver
Caution
Miratas-25 Tablet should be used with caution in patients with severe liver disease. A dose adjustment of Miratas-25 Tablet may be needed. Please consult your doctor. Miratas-25 Tablet is not recommended for use in patients with severe liver disease.
Kidney
Caution
Miratas-25 Tablet should be used with caution in patients with kidney disease. A dose adjustment of Miratas-25 Tablet may be needed. Please consult your doctor.
Children
Caution
Miratas-25 Tablet should not be used in children below 12 years of age unless prescribed by a doctor.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes